“Our first procedure with the MVP-5 was consistent with our prior experience with the MVP-3, resulting in accurate and immediate vessel occlusion upon deployment. The device tracked easily through tortuous anatomy, allowing for more precise control than conventional embolization coils. The MVP product line has become an essential device in my lab,” said Rahul Patel, M.D., assistant professor, Interventional Radiology, at Mount Sinai Hospital in New York, NY.
Microcatheter deliverability enables treatment of distal, superselective vessels for targeted treatment. Further, the device is fully resheathable to facilitate accurate placement. The firm touted that the technology could have a strong economic benefit for both patients and physicians.
Reverse Medical Vice President Global Sales Alex Thomson noted, “The MVP-5 Micro Vascular Plug system represents an important addition to the MVP product line worldwide, soon to be followed by an MVP-7 and MVP-9, addressing a broad spectrum of peripheral vascular anatomy. Physician enthusiasm from MVP-3 clinical use created strong demand for larger sizes, and we quickly responded. Embolization coils have been known to be the favored device for vessel occlusion, largely because of no available alternative technology. The MVP is a platform technology with broad clinical utility for peripheral and eventual additional indications throughout the body.”
Reverse Medical Corporation is a privately held medical device company that develops endovascular treatments for various peripheral and neurovascular disorders and diseases. The company is based in Irvine, California.